Medidata Solutions will be showcasing new products, presenting in educational sessions and demonstrating key integrations at this week’s 47th Annual Meeting of the Drug Information Association (DIA) in Chicago, Ill.
“Through our executive presentations, booth demonstrations and participation in the Interoperability Showcase, we look forward to showcasing Medidata's approach to helping clinical researchers optimize their clinical trials at the DIA Annual Meeting," said Tarek Sherif, chairman and CEO of Medidata Solutions. "We will be introducing new products and capabilities and demonstrating our full product platform as we participate in the industry's premier networking and education event."
New Products Address Sponsor Pain Points Across Clinical Development Chain
From booth #1101, Medidata will be providing demos of key products, including:
Medidata Rave Integrates with EMRs at Interoperability Showcase
Medidata is also sponsoring DIA’s inaugural Interoperability Showcase. The Showcase, led by DIA, CDISC, HIMSS and the IHE, will offer demonstrations of new solutions that facilitate improved clinical research and safety reporting capabilities.
In the Showcase, Medidata will demonstrate integrations with electronic medical records (EMRs) and other systems, highlighting how standards-based IT solutions can improve data information exchange between systems, providers and organizations to optimize clinical care and research.
Executive Speakers Drive Discussion on Key Topics and Trends in Research and Development
Medidata executives will be leading the following sessions this week:
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.